Testicular, prostate and bladder cancer sit in an awkward corner of men’s health. They involve body parts men joke about rather than describe, the early symptoms are easy to explain away, and the screening conversation has become so tangled in debate that plenty of men decide the simplest option is to do nothing. That is the worst of the available choices. The better one is to understand what each of these cancers actually does, what a reasonable check involves at different ages, and when a symptom deserves a same-week appointment rather than a wait-and-see.
Three cancers, three very different shapes
Lumping them together as “men’s cancers” hides how differently they behave. Treating them as one topic is why men end up worrying about the wrong thing at the wrong age.
Testicular cancer: young men, fast growth, high curability
This is predominantly a disease of younger men — roughly the late teens to late thirties — which makes it the one cancer most likely to be dismissed as “I’m too young for that”. It typically announces itself as a painless firm lump or swelling in one testicle, a change in size or weight, or a dull ache in the groin or lower abdomen. Undescended testicle in infancy and a family history both raise risk. Growth can be quick, which is exactly why a new lump should be assessed within days, not months. A doctor’s examination plus a scrotal ultrasound usually resolves the question rapidly, and blood tumour markers help clarify the picture.
Prostate cancer: common, often slow, sometimes not
Prostate cancer is overwhelmingly a disease of later life, with risk climbing steeply after 50, and earlier for men with African ancestry or a first-degree relative diagnosed young. The central difficulty is that it spans a huge spectrum. Some tumours are so indolent they will never trouble a man in his lifetime; others are aggressive from the outset. Early disease usually causes no symptoms at all. Urinary changes — weak flow, hesitancy, waking repeatedly at night — are far more often benign enlargement than cancer, but they are still worth reporting. Blood in the urine or semen, new bone pain or unexplained weight loss raise the urgency considerably.
Bladder and urothelial cancer: the one with the clearest red flag
Bladder cancer has the most useful single warning sign in urology: visible blood in the urine, usually painless, sometimes appearing once and then vanishing for weeks. That disappearance is a trap. One episode of visible haematuria in an adult warrants investigation even if everything looks normal afterwards. Smoking is by far the dominant modifiable risk factor, and occupational exposure to certain industrial chemicals matters too. Recurrent urinary infections that never quite clear, or persistent urgency without infection, also deserve a second look.
The screening question, answered honestly
There is no population screening programme for testicular or bladder cancer, because the maths does not support it — the diseases are too uncommon in the general population for a mass test to do more good than harm. For testicular cancer, self-familiarity is the practical substitute: a brief check in the shower every few weeks, so you know what normal feels like for you and would notice a change.
Prostate cancer is different because a blood test exists. PSA (prostate-specific antigen) testing can detect disease before symptoms appear, but it is not a yes-or-no cancer test. PSA rises with benign enlargement, inflammation, infection, recent cycling and sometimes sex. A raised result may lead to further imaging or biopsy, and a biopsy can find a slow-growing tumour that would never have caused harm — which then creates a decision about whether to treat or monitor. That is the trade-off, stated plainly: earlier detection of dangerous cancers, at the cost of some anxiety and some investigation of harmless ones.
The sensible resolution is not to refuse the test or to demand it reflexively, but to have a short, informed conversation at around 50 — or around 45 with a strong family history — about whether testing fits your risk profile and your temperament. If you do test, a single result in isolation tells you less than a trend over time. Ask for your number, write it down, and track it.
Why the care team matters more than any single machine
Once there is a suspicion of urological cancer, outcomes depend heavily on coordination. A urologist, medical oncologist, radiation oncologist, radiologist and pathologist each hold a different piece of the picture, and the decisions that follow — surgery versus radiotherapy, immediate treatment versus active surveillance, which systemic therapy and in what order — are rarely made well in isolation. This is the logic behind structured specialty care pathways and multidisciplinary review, an approach that health systems have deliberately built policy around; the key concepts behind coordinated specialty care describe why handoffs between specialists are where quality is most often won or lost.
In practice, the questions worth asking at a first appointment are unglamorous but revealing. Will my case be discussed by a multidisciplinary team, or decided by one clinician? Who reads my imaging — a general radiologist or someone who looks at cancer scans daily? Who interprets my biopsy? What are the alternatives to the treatment you are proposing, and what does each cost me in terms of continence, sexual function and recovery time? A specialist who answers those comfortably is a good sign.
Where specialist programmes come in
For men in the Gulf, or those travelling for treatment, the practical advantage of a dedicated programme is that the whole pathway sits under one roof rather than being assembled appointment by appointment. Cleveland Clinic Abu Dhabi’s Cancer Institute runs distinct programmes for testicular, prostate and bladder or urothelial cancer, covering diagnosis, surgery, medical oncology and radiation oncology, with dedicated cancer imaging and pathology specialists and cases reviewed through a multidisciplinary Tumor Board in collaboration with Cleveland Clinic in the US. On the prostate side, that includes PSA testing and diagnostics alongside treatment options such as High-Intensity Focused Ultrasound (HIFU), stereotactic radiotherapy and Ethos adaptive radiotherapy, so a man weighing surgery against radiation can see a Prostate cancer doctor and discuss the full range in one place rather than being referred piecemeal across the city.
Separating evidence from supplement-shop promises
Men researching prostate health online run into an industry of pills, injectables and “hormone optimisation” protocols promising prevention or recovery. Be sceptical, and be specific in your scepticism: ask what the product contains, who tested it and whether the batch you are buying was independently verified. Anyone tempted by the research-chemical end of that market should at least understand what proper documentation looks like, and why a certificate of analysis and batch verification is the minimum standard before anything enters your body. None of it substitutes for a diagnosis.
A short, practical plan
- Under 40: get familiar with your own anatomy and act on any new testicular lump, swelling or ache within a week.
- Any age: visible blood in the urine is a one-off reason to see a doctor, even if it stops.
- If you smoke, quitting is the single most effective thing you can do for bladder cancer risk.
- Around 45 to 50: have the PSA conversation, factoring in family history and ancestry, and keep a record of results.
- Persistent urinary changes lasting more than a few weeks deserve assessment rather than adaptation.
- If diagnosed, ask who sits on the team reviewing your case before you agree to a treatment plan.
None of this requires courage so much as a diary entry. The men who do badly with urological cancers are rarely the ones who were unlucky with symptoms — they are usually the ones who noticed something, told themselves it was probably nothing, and gave it six months to prove them right.
For more, visit Pure Magazine

